Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended

2023-505219-19-00 Relapsed or refractory multiple myeloma (RRMM) and newl 9 2019-09-03
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Advanced Malignancies 5 2019-08-09
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended

2023-507405-34-00 First-line patients with advanced biliary tract cancers 5 2019-08-07
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended

2023-507582-25-00 Malignant Extracranial Germ Cell Tumours (MGCT) 5 2019-08-02
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l… Ended

2022-502616-37-00 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r 9 2019-07-30
EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended

2023-508478-27-00 Advanced stage Hodgkin Lymphoma 4 2019-07-30
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended

2023-506153-38-00 High-risk localized or locally advanced prostate cancer 5 2019-07-11
A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended

2024-511646-40-00 First-line (1L) Stage IV Triple Negative Breast Cancer 9 2019-07-11
A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f… Ended

2024-514705-62-00 Recurrent rectal cancer after local excision 5 2019-07-08
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after i… Ended

2024-512564-58-00 EGFRm+ and MET+, Locally Advanced or Metastatic Non Sma 4 2019-07-05
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended

2023-509287-26-00 previously untreated metastatic or locally advanced eso 4 2019-07-01
A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended

2023-509605-77-00 Advanced solid tumours 1 2019-06-27
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated… Ended

2024-516478-31-00 progressed thyroid cancer 5 2019-06-12
Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiation Ended

2023-510268-11-00 Cervical cancer 4 2019-06-11
A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended

2023-508264-29-00 Advanced Renal Cell Carcinoma with Intermediate- or Poo 5 2019-06-11
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi… Ended

2024-511798-31-00 KRAS p.G12C Mutant Advanced Solid Tumors 7 2019-05-31
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i… Ended

2024-513277-52-00 Patients with Advanced Gastrointestinal Stromal Tumors 5 2019-05-20
Safety and efficacy of BL-8040 with G-CSF compared to Placebo with G-CSF for the collection of peripheral blood stem cells for autologous tr… Ended

2024-511953-23-00 Hematopoietic Stem Cell mobilization autologous transpl 5 2019-05-17